Cite
HARVARD Citation
Pavel, M. et al. (2021). Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. European journal of cancer. pp. 403-414. [Online].